Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRBP Corbus Pharmaceuticals Holdings, Inc.

已收盘 09-28 16:00:00 EDT

6.92

-0.22

-3.08%

盘后6.92

+0.000.00%

19:52 EDT

最高7.18	最低6.88	成交量93.20万
今开7.12	昨收7.14	日振幅4.20%
总市值1.34亿	流通市值1.21亿	总股本1,934万
成交额651.55万	换手率5.35%	流通股本1,742万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals Holdings, Inc.","latestPrice":6.92,"timestamp":1790625600000,"preClose":7.14,"halted":0,"volume":932034,"hourTrading":{"tag":"盘后","latestPrice":6.92,"preClose":6.92,"latestTime":"19:52 EDT","volume":43481,"amount":300902.8735,"timestamp":1790639552307,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.030812324929971956,"floatShares":17416483,"shares":19341300,"eps":-6.088859,"marketStatus":"已收盘","change":-0.22,"latestTime":"09-28 16:00:00 EDT","open":7.12,"high":7.18,"low":6.88,"amount":6515515.093794,"amplitude":0.042017,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.088859,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790668800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":7.14,"preHourTrading":{"tag":"盘前","latestPrice":7.0401,"preClose":7.14,"latestTime":"09:19 EDT","volume":1263,"amount":9012.668222999999,"timestamp":1790601549645,"change":-0.0999,"changeRate":-0.013992,"amplitude":0.029636},"postHourTrading":{"tag":"盘后","latestPrice":6.92,"preClose":6.92,"latestTime":"19:52 EDT","volume":43481,"amount":300902.8735,"timestamp":1790639552307,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.452663,"impliedVol":1.136,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/CRBP/tweets","defaultTab":"tweets","newsList":[{"id":"1124091603","title":"Corbus Pharmaceuticals：CRB-913治疗因不良事件中止率介于3.1%至13.1%之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1124091603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124091603?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:02","pubTimestamp":1789383730,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings披露，其候选药物CRB-913在临床试验中，因不良事件导致的治疗中止率跨度显著——从最低的3.1%到最高达13.1%。这一数据区间反映出不同剂量或患者群体间的安全性差异，也凸显了该药物在耐受性方面仍需审慎评估。对于正在推进研发管线的Corbus而言，如何在疗效与安全性之间取得平衡，将是后续开发进程中的关键考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150073678","title":"Corbus Pharmaceuticals公布每日口服CRB-913治疗肥胖症Canyon-1研究积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1150073678","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150073678?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:02","pubTimestamp":1789383726,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.今日宣布，其针对每日口服疗法CRB-913用于肥胖症治疗的Canyon-1研究，已取得积极的顶线数据结果。这一进展，无疑为该公司在代谢疾病领域的布局注入了强劲动能。数据出炉之际，市场目光再度聚焦于这家生物制药企业身上。此项研究的详细成果备受期待，其背后所承载的，是无数患者对新治疗选择的迫切渴望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177957644","title":"Corbus Pharmaceuticals预计2027年上半年启动CRB-913单药疗法二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1177957644","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177957644?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:01","pubTimestamp":1789383679,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings宣布，该公司预计将在2027年上半年前启动CRB-913的二期单药疗法临床研究。这一时间表标志着该候选药物研发进程中的又一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148145822","title":"Corbus Pharmaceuticals Holdings: CRB-913展现良好耐受性，精神及胃肠道不良事件特征积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1148145822","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148145822?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:01","pubTimestamp":1789383677,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.旗下在研药物CRB-913，在临床评估中展现出令人满意的耐受性，其精神类及胃肠道不良事件特征亦呈现出有利态势。这一积极信号，无疑为这款候选药物的后续开发注入了更多信心与期待。具体而言，该药物在受试群体中的表现，不仅整体安全性可控，更在常令人担忧的两个关键副作用领域，交出了较为理想的答卷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111684063","title":"Corbus Pharmaceuticals 旗下 Crb-913 数据彰显口服非肠促胰岛素类肥胖药物新前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1111684063","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111684063?lang=zh_cn&edition=full","pubTime":"2026-09-14 19:01","pubTimestamp":1789383670,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 近日发布的 Crb-913 临床数据，为口服非肠促胰岛素类肥胖治疗药物的研发注入了新的活力。值得注意的是，Crb-913 的作用机制与传统疗法截然不同，其早期研究结果显示，该药物在体重管理方面展现出了令人鼓舞的疗效和可接受的安全性特征。业内专家指出，若后续研究能够进一步验证这些初步成果，Crb-913 有望在竞争激烈的肥胖药物市场中占据一席之地，为那些对现有疗法反应不佳或不耐受的患者带来全新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183859650","title":"Corbus Pharmaceuticals 计划通过 Jefferies 发行并出售高达 1.275 亿美元的普通股——SEC 文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1183859650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183859650?lang=zh_cn&edition=full","pubTime":"2026-08-08 04:47","pubTimestamp":1786135650,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 在最新提交的 SEC 文件中披露，公司计划通过 Jefferies 发行并出售普通股，总额高达 1.275 亿美元。这一举措旨在筹集资金，可能用于研发、运营或其他战略用途。市场对此消息反响积极，投资者关注后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190665325","title":"Corbus Pharmaceuticals宣布：CRB-913治疗肥胖症Canyon-1研究完成最后一名患者末次访视","url":"https://stock-news.laohu8.com/highlight/detail?id=1190665325","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190665325?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:31","pubTimestamp":1785846677,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals于今日正式披露，其针对肥胖症治疗的CRB-913所开展的Canyon-1研究，已顺利完成最后一名患者的末次访视。所有参与研究的受试者，均已完成按照既定方案要求的所有访视及评估流程。Corbus管理层对此表示，这一成果的达成，为后续的数据分析工作奠定了坚实基础。Corbus的CRB-913作为一种新型候选药物，其临床数据的安全性及有效性表现，备受市场与投资者的关注。下一步，Corbus将进入更为关键的数据库锁定与统计分析阶段，为最终向监管机构提交申请铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172107419","title":"Corbus Pharmaceuticals 获FDA许可，启动CRB-701治疗二线口咽癌的Tempo-1注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1172107419","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172107419?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240069,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals宣布，已获得美国食品药品监督管理局（FDA）的批准，得以启动一项名为Tempo-1的注册研究。该研究旨在评估CRB-701在二线口咽癌患者中的疗效与安全性。这一里程碑式的进展，标志着公司在肿瘤治疗领域的管线迈入关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167304047","title":"CRBP旗下CRB-701整体安全性良好，停药率低于3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167304047","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167304047?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:04","pubTimestamp":1779793453,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.（CRBP）公布的其候选药物CRB-701的临床数据显示，该药物整体表现出良好的安全性和耐受性。\n在临床试验中，因不良事件导致的停药率被控制在3%以下，这一数据为后续开发提供了积极的安全信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146023842","title":"Corbus Pharmaceuticals公布CRB-701药物1/2期临床试验最新数据，在二线治疗口咽癌与宫颈癌中展现强劲活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1146023842","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146023842?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:03","pubTimestamp":1779793400,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals披露了其候选药物CRB-701的1/2期临床试验最新数据。这些更新结果显示，该药物在治疗二线口咽癌和宫颈癌患者中，表现出显著的抗肿瘤活性。\n临床数据揭示了CRB-701在目标患者群体中的积极疗效信号，为后续开发提供了有力支持。这一进展凸显了该疗法在应对这些癌症类型方面的潜力。\n公司基于这些令人鼓舞的结果，将继续推进CRB-701的临床开发计划。后续研究将致力于进一步评估其安全性与有效性，以期为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198768990","title":"Corbus Pharmaceuticals 计划今夏启动CRB-701用于二线头颈癌的注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1198768990","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198768990?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:03","pubTimestamp":1779365009,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 宣布，将于今年夏季启动一项针对CRB-701在二线头颈部鳞状细胞癌治疗中的注册研究。此举标志着该公司在推进其核心候选药物方面迈出了关键一步，旨在满足该治疗领域未满足的临床需求。\n这项即将开展的注册研究旨在评估CRB-701在特定患者群体中的疗效与安全性，为后续的监管申报提供关键数据支持。头颈癌领域存在巨大的医疗需求，新疗法的开发备受关注。\n公司选择在夏季启动研究，展现了其加速研发进程的战略部署。随着研究的推进，相关临床数据将成为市场关注的焦点，并可能对公司的未来发展产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197712302","title":"Corbus Pharmaceuticals任命Nishant Saxena为首席商务官，并计划召开2026年ASCO会议前CRB-701数据电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197712302","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197712302?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:01","pubTimestamp":1779364887,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.  宣布，已任命Nishant Saxena为公司首席商务官。与此同时，该公司还安排了一场电话会议，计划在2026年美国临床肿瘤学会年会之前，重点讨论其候选药物CRB-701的相关数据。会议的核心议题将围绕CRB-701的临床数据展开，该药物是公司研发管线中的重要资产。此次沟通旨在向投资者和分析师更新该候选药物的最新进展，并为即将到来的2026年ASCO年会进行预热。通过这一系列举措，Corbus Pharmaceuticals展现了其在推进临床项目与加强团队建设方面的双重努力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108601446","title":"Guggenheim首予Corbus Pharmaceuticals买入评级 目标价45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108601446","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108601446?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:17","pubTimestamp":1777432638,"startTime":"0","endTime":"0","summary":"投资机构Guggenheim近日首次覆盖生物制药公司Corbus Pharmaceuticals Holdings Inc，给予\"买入\"评级，并设定45美元的目标股价。\n此次覆盖标志着华尔街对这家专注于炎症和肿瘤领域创新疗法研发的企业投下信任票。目标价的设定也反映出分析师对该司未来增长潜力的积极预期。\nCorbus Pharmaceuticals目前正在推进多项临床阶段候选药物，其核心产品线针对纤维化疾病和癌症治疗领域。Guggenheim的买入评级或将进一步提升市场对该公司的关注度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129593717","title":"Corbus Pharmaceuticals宣布Canyon-1研究中最后一名患者首次接受CRB-913肥胖治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129593717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129593717?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:03","pubTimestamp":1776168237,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 已宣布，在其针对肥胖治疗的CRB-913药物Canyon-1研究中，最后一名患者完成了首次访视。这一进展标志着该研究的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134165905","title":"Corbus Pharmaceuticals Holdings Inc 将继续与FDA沟通以敲定注册研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1134165905","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134165905?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563280,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings Inc (CRBP) 宣布，公司计划持续推进与美国食品药品监督管理局（FDA）的互动，旨在最终确定其关键注册研究的试验方案。这一步骤对于公司后续的新药申报及商业化进程至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193537309","title":"Corbus Pharmaceuticals与FDA就CRB-701在二线头颈癌及宫颈癌的注册路径达成广泛共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1193537309","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193537309?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563275,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 宣布，其与FDA就CRB-701在二线头颈鳞状细胞癌及宫颈癌的注册路径达成了广泛共识。这一进展标志着公司在推进该候选药物治疗方案方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180008347","title":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)","url":"https://stock-news.laohu8.com/highlight/detail?id=1180008347","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180008347?lang=zh_cn&edition=full","pubTime":"2025-03-11 21:00","pubTimestamp":1741698029,"startTime":"0","endTime":"0","summary":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)以上内容来自Benzinga Earnings专栏，原文如下：Corbus Pharmaceuticals Q4 EPS $(0.78) Beats $(1.20) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637872","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516637872?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:03","pubTimestamp":1741014224,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时03分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速下跌5.10%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230345a25d49c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230345a25d49c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320289","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 股价大涨7.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320289?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753065,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Corbus Pharmaceuticals Holdings, Inc.股票出现波动，股价大幅上涨7.50%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231059896796e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231059896796e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513372082","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 快速下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513372082?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:54","pubTimestamp":1740408851,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时54分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速下跌5.26%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225411962e9e81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225411962e9e81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0455},{"period":"1month","weight":-0.3681},{"period":"3month","weight":-0.1831},{"period":"6month","weight":-0.1803},{"period":"1year","weight":-0.4119},{"period":"ytd","weight":-0.1229}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Corbus Pharmaceuticals Holdings, Inc.于2009年4月24日根据特拉华州法律注册成立。Corbus是一家精准肿瘤学公司，拥有多元化的产品组合，致力于通过将创新的科学方法引入已被广泛理解的生物途径，帮助人们战胜严重疾病。该公司的管线由两种针对实体瘤的实验药物组成：CRB-701，一种下一代抗体药物偶联物，靶向Nectin-4在癌细胞上的表达以释放细胞毒性有效载荷，CRB-601，一种抗整合素单克隆抗体，可阻断癌细胞上表达的TGFβ的激活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055971},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044414},{"month":7,"riseRate":0.25,"avgChangeRate":-0.049826},{"month":8,"riseRate":0.666667,"avgChangeRate":0.105723},{"month":9,"riseRate":0.25,"avgChangeRate":-0.108044},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals Holdings, Inc.","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corbus Pharmaceuticals Holdings, Inc.(CRBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corbus Pharmaceuticals Holdings, Inc.,CRBP,Corbus Pharmaceuticals Holdings, Inc.股票,Corbus Pharmaceuticals Holdings, Inc.股票老虎,Corbus Pharmaceuticals Holdings, Inc.股票老虎国际,Corbus Pharmaceuticals Holdings, Inc.行情,Corbus Pharmaceuticals Holdings, Inc.股票行情,Corbus Pharmaceuticals Holdings, Inc.股价,Corbus Pharmaceuticals Holdings, Inc.股市,Corbus Pharmaceuticals Holdings, Inc.股票价格,Corbus Pharmaceuticals Holdings, Inc.股票交易,Corbus Pharmaceuticals Holdings, Inc.股票购买,Corbus Pharmaceuticals Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corbus Pharmaceuticals Holdings, Inc.(CRBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}